

Anti-ERBB2/HER2/CD340 Antibody (Trastuzumab emtansine)

Introduction

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-conjugated molecule (ADC) that combines the antitumor properties of the HER2-targeting trastuzumab with the cytotoxic activity of the microtubule inhibitor DM1. Trastuzumab emtansine is being investigated in advanced breast cancer.

Product parameters

Alternative Names	Kadcyla, PRO132365, trastuzumab-MCC-DM1
Target Accession	P04626
Target	ERBB2 / HER2 / CD340
CAS number	1018448-65-1
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	DM1
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	-
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

